Meningitis, Meningococcal: all 125 studies

Page 1 of 2. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.

• Single-center, Open-label Study: Immunogenicity and Safety Observation After Vaccination With ACYW135 Meningococcal Polysaccharide Vaccine in Junior High School Students Aged 13-15 YearsNot yet recruitingNCT07885371Phase 4
• A Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector)Not yet recruitingNCT07743411
• Metagenomic Analysis of the Pharynx in High Risk PartnersNot yet recruitingNCT07671014
• Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 MonthsRecruitingNCT07505836Phase 3
• Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 MonthsRecruitingNCT07505823Phase 3
• Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 MonthsRecruitingNCT07505810Phase 3
• Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate VaccineNot yet recruitingNCT07374510Phase 1
• Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined VaccineRecruitingNCT07203755Phase 1
• Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender PersonsRecruitingNCT06832514Phase 4
• A Study of the ACYW135 Meningococcal Polysaccharide Conjugate VaccineNot yet recruitingNCT06337071Phase 2
• Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY VaccineCompletedNCT04707391Phase 3Results posted
• Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedNCT03621670Phase 3Results posted
• Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 YearsCompletedNCT03587207Phase 2Results posted
• A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14TerminatedNCT03549325Not applicableResults posted
• Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in EuropeCompletedNCT03547271Phase 3Results posted
• Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USCompletedNCT03537508Phase 3Results posted
• A Sourcing Study to Collect Human Blood Samples From Healthy AdultsCompletedNCT03493919Phase 4Results posted
• Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in ChildrenCompletedNCT03476135Phase 3Results posted
• A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of AgeCompletedNCT03433482Phase 2Results posted
• Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month OldsCompletedNCT03295318Phase 2Results posted
• Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in ToddlersCompletedNCT03205371Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT03205358Phase 2Results posted
• Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 YearsCompletedNCT03077438Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in ToddlersCompletedNCT02955797Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and OlderCompletedNCT02842866Phase 3Results posted
• Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02842853Phase 3Results posted
• Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02752906Phase 3Results posted
• Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in VietnamCompletedNCT02640404Phase 2Results posted
• Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years EarlierCompletedNCT02633787Phase 4Results posted
• Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult SubjectsCompletedNCT02591290Phase 4Results posted
• Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.CompletedNCT02305446Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsCompletedNCT02199691Phase 2Results posted
• Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate VaccineCompletedNCT01897402Phase 2Results posted
• Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28CompletedNCT01894919Phase 3Results posted
• Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of AgeCompletedNCT01768117Phase 2Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young AdultsCompletedNCT01755689Phase 3Results posted
• Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and OlderCompletedNCT01732627Phase 2Results posted
• Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1CompletedNCT01717638Phase 3Results posted
• Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese SubjectsCompletedNCT01519713Phase 3Results posted
• A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk AdultsCompletedNCT01478347Phase 3Results posted
• A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsCompletedNCT01466387Phase 3Results posted
• Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate VaccineCompletedNCT01453348Phase 3Results posted
• Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy ToddlersCompletedNCT01434680Phase 2Results posted
• A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in AdolescentsCompletedNCT01424644Phase 4Results posted
• Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 YearsCompletedNCT01423084Phase 3Results posted
• Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study VaccinesCompletedNCT01367158Phase 2Results posted
• A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 YearsCompletedNCT01352793Phase 3Results posted
• A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 YearsCompletedNCT01339923Phase 3Results posted
• A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in KoreaCompletedNCT01274897Phase 3Results posted
• Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial VaccinationCompletedNCT01239043Phase 2Results posted
• Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of LifeCompletedNCT01214837Phase 3Results posted
• Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10CompletedNCT01148524Phase 2/3Results posted
• Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate VaccineCompletedNCT01148017Phase 3Results posted
• A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWYCompletedNCT01018732Phase 2Results posted
• Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12CompletedNCT00944034Phase 2/3Results posted
• Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old InfantsCompletedNCT00937521Phase 2Results posted
• Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy AdultsCompletedNCT00879814Phase 1Results posted
• Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 YearsCompletedNCT00874549Phase 1/2Results posted
• Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate VaccineCompletedNCT00856297Phase 3Results posted
• A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In AdolescentsCompletedNCT00808028Phase 2Results posted
• Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy InfantsTerminatedNCT00798304Phase 2Results posted
• The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy ToddlersCompletedNCT00718666Phase 2Results posted
• Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and ToddlersCompletedNCT00667602Phase 3Results posted
• Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsCompletedNCT00657709Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In AdolescentsCompletedNCT00518180Phase 3Results posted
• Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersCompletedNCT00483574Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsCompletedNCT00474526Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy AdultsCompletedNCT00474487Phase 3Results posted
• A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and AdultsCompletedNCT00450437Phase 3Results posted
• RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)CompletedNCT00443846Phase 3Results posted
• Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy ToddlersCompletedNCT00422292Phase 3Results posted
• A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT00384397Phase 3Results posted
• Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®CompletedNCT00355121Phase 2Results posted
• Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 YearsCompletedNCT00329901Phase 3Results posted
• Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)CompletedNCT00310856Phase 2Results posted
• Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.CompletedNCT00310817Phase 2Results posted
• Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.CompletedNCT00248833Phase 1Results posted
• Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 YearsActive, not recruitingNCT07505888Phase 3
• A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year OldsCompletedNCT06700148Phase 3
• Clinical Study of the Safety of Menhycia® in 3-Month-Old InfantsCompletedNCT06389513Phase 4
• A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year OldsActive, not recruitingNCT06226714Phase 3
• A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 YearsCompletedNCT06131554Phase 3
• A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of AgeActive, not recruitingNCT06113198Phase 4
• A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old PopulationCompletedNCT06011200Phase 3
• Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)Active, not recruitingNCT05935176Phase 4
• Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 MonthsStatus unknownNCT05252715Phase 3
• Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 MonthsCompletedNCT05229536Phase 2
• Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy AdolescentsActive, not recruitingNCT05087056Phase 2
• A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide VaccineCompletedNCT04689191Phase 3
• A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide VaccineStatus unknownNCT04689165Phase 3
• Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura FulminansTerminatedNCT04685850
• A Human Controlled Infection Study with Neisseria Lactamica in Malian AdultsCompletedNCT04665791Not applicable
• Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive InfectionStatus unknownNCT04594785
• A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 YearsCompletedNCT04450498Phase 4
• Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.CompletedNCT04236960Phase 1
• Sero-epidemiological Survey of England in 2019/2020 - COVID-19CompletedNCT04061382
• Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)CompletedNCT03964012Phase 3
• High and Low Resource Interventions to Promote HPV VaccinesCompletedNCT03824093Not applicable
• Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk PopulationStatus unknownNCT03682939Phase 4
• Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018WithdrawnNCT03431675Phase 4

← Meningitis, Meningococcal overview